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BACKGROUND: ErbB2 is an attractive target for immunotherapy, as it is a tyrosine kinase receptor overexpressed on tumour cells of
different origin, with a key role in the development of malignancy. Trastuzumab, the only humanised anti-ErbB2 antibody currently
used in breast cancer with success, can engender cardiotoxicity and a high fraction of patients is resistant to Trastuzumab treatment.
METHODS: A novel human immunoRNase, called anti-ErbB2 human compact antibody-RNase (Erb-hcAb-RNase), made up of the
compact anti-ErbB2 antibody Erbicin-human-compact Antibody (Erb-hcAb) and human pancreatic RNase (HP-RNase), has been
designed, expressed in mammalian cell cultures and purified. The immunoRNase was then characterised as an enzymatic protein, and
tested for its biological actions in vitro and in vivo on ErbB2-positive tumour cells.
RESULTS: Erb-hcAb-RNase retains the enzymatic activity of HP-RNase and specifically binds to ErbB2-positive cells with an affinity
comparable with that of the parental Erb-hcAb. Moreover, this novel immunoRNase is endowed with an effective and selective
antiproliferative action for ErbB2-positive tumour cells both in vitro and in vivo. Its antitumour activity is more potent than that of the
parental Erb-hcAb as the novel immunoconjugate has acquired RNase-based cytotoxicity in addition to the inhibitory growth effects,
antibody-dependent and complement-dependent cytotoxicity of Erb-hcAb.
CONCLUSION: Erb-hcAb-RNase could be a promising candidate for the immunotherapy of ErbB2-positive tumours.
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Immunotherapy is a precious strategy to overcome the limits of the
conventional anticancer treatments. Indeed, targeting cancer cells
via antibodies specific for tumour-associated surface proteins
could fulfil the lack of selectivity of radiotherapy and chemo-
therapy, and is a new interesting biomedical approach as it
combines the rational drug design with the progress in under-
standing cancer biology.
To date, several humanised monoclonal antibodies (MAbs) have
achieved FDA approval, and an increasing number is undergoing
clinical evaluation (Harris, 2004; Adams and Weiner, 2005;
Venkiteshwaran, 2009; Li and Zhu, 2010). A successful example of
an approved humanised antibody is represented by Trastuzumab,
the only humanised antibody widely used against ErbB2-positive
carcinomas for immunotherapy (Stebbing et al, 2000).
ErbB2 is an attractive target for immunotherapy, as it is a
transmembrane tyrosine kinase receptor, overexpressed on
tumour cells of different origin, with a key role in the development
of malignancy (Slamon et al, 1987). Trastuzumab is currently used
with success for breast cancer therapy; however, it can engender
cardiotoxicity and a high fraction of breast cancer patients is
resistant to Trastuzumab treatment (Seidman et al, 2002; Nahta
et al, 2006).
Furthermore, also carcinomas with a high expression of ErbB2,
such as non-small cell lung carcinoma, gastric and prostatic
tumours, have been found to be resistant or much less sensitive to
Trastuzumab treatment (Agus et al, 1999; Gong et al, 2004). When
Trastuzumab was used in combination with chemotherapy, some
benefits have been shown in clinical trials for patients, such as
those with ErbB2-positive advanced gastric cancer (Jørgensen,
2010), but cardiac dysfunction has also been observed more
frequently (Seidman et al, 2002).
A significant addition to the anticancer arsenal has been the
construction of a new anti-ErbB2 immunoagent derived from a
human, per se cytotoxic single-chain antibody fragment (scFv)
named Erbicin (De Lorenzo et al, 2002b), and a human Fc domain
from a human IgG1. This led to a fully human antitumour
antibody, designed to be a reduced version of an IgG, with the
antiproliferative effect of the scFv moiety on tumour target cells,
combined with the ability of the Fc moiety to induce both
antibody-dependent cellular cytotoxicity (ADCC) and comple-
ment-dependent cytotoxicity (CDC).
The engineered antibody has been called Erbicin-human-
compact Antibody (Erb-hcAb) for its ‘compact’ size (100kDa),
compared with the full size (155kDa) of a natural IgG. The smaller
size should promote an increased extravascular diffusion and
tumour penetration.
It has been reported that Erb-hcAb is capable of selective
binding to malignant ErbB2-positive cells and of inhibiting their
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sgrowth in vitro and in vivo, with no effects on ErbB2-negative cells.
Moreover, Erb-hcAb is endowed with both ADCC and CDC
cytotoxic effects, whereas Trastuzumab lacks the ability of
inducing CDC (De Lorenzo et al, 2004b).
More recently, it has been shown that Erb-hcAb does not display
the cardiotoxic effects of Trastuzumab in vitro on rat cardiomyo-
cytes and in vivo on a mouse model (Riccio et al, 2009), whereas
Trastuzumab was found to be strongly toxic. This difference was
found to be due to the different mechanism of action of the two
antibodies: Trastuzumab, at difference with Erb-hcAb, induces
apoptosis in cardiac cells (Riccio et al, 2009). Finally, Erb-hcAb is
active in vitro and in vivo against some Trastuzumab-resistant,
ErbB2-positive breast cancer cell lines (Gelardi et al, 2010).
Targeted therapy can be accomplished also by using MAbs
equipped with radionuclides or toxins (Pastan and FitzGerald,
1991; Carter, 2001). Immunotoxins (ITs) are anticancer agents
made up of a recombinant antibody or an antibody fragment
directed towards a unique cell surface protein and a potent
bacterial toxin capable of inducing the death of target cells (Reiter
and Pastan, 1998; Zhang et al, 2007).
However, problems have been encountered in clinical trials,
especially for the toxicity and immunogenicity of the bacterial or
plant toxins used for the ITs (Weiner et al, 1989; Schindler et al,
2001).
As an alternative to ITs, ImmunoRNases (IRs) have been
proposed as more immunocompatible immunoagents. These are
fusion proteins in which the toxin has been replaced by a
ribonuclease. Mammalian RNases are expected to be not
immunogenic and not systemically toxic, as they are pro-toxins,
which become toxic only upon their internalisation in target cells
mediated by the antibody moiety (Rybak and Newton, 1999;
De Lorenzo et al, 2002a; De Lorenzo and D’Alessio, 2008).
A fully human immunoRNase, Erbicin-human-RNase (Erb-
hRNase), was constructed through the fusion of Erbicin with
human pancreatic RNase (HP-RNase or RNase 1) (De Lorenzo
et al, 2004a). The chimeric protein was found to retain the high-
binding affinity to ErbB2-positive cells of Erbicin and the
enzymatic activity of native HP-RNase. When tested in vitro on
a series of malignant cells, Erb-hRNase was found to discriminate
between target and non-target cells, and to specifically inhibit the
proliferation of ErbB2-positive cells, with a stronger cytotoxicity
on cells with a higher level of ErbB2. Its antitumour activity has
been also demonstrated in vivo on mice implanted with ErbB2-
positive tumours (De Lorenzo et al, 2004a; De Lorenzo and
D’Alessio, 2009).
The antitumour action of Erb-hRNase is dependent on the
ability of this molecule to reach the cytosol and degrade RNA, but
it is somewhat limited by the finding (De Lorenzo et al, 2007) that
the enzymatic activity of Erb-hRNase is inhibited by the RNase
inhibitor (RI).
In order to obtain a novel product, which is expected to be
superior to the immunoagents currently used in the therapy of
breast cancer, a novel immunoRNase has been designed, in which
an Erbicin-based scFv-Fc (Erb-hcAb, see above) replaces the scFv
of Erb-hRNase. The latter should have the following advantages:
the ability of inducing both ADCC and CDC, in addition to the
RNase-based cytotoxicity; a prolonged half-life, due to its higher
molecular size and the presence of the Fc and an increased
avidity due to the presence of two scFv moieties. Furthermore, this
novel immunoagent could be resistant to the action of RI, due to
the steric hindrance generated by the presence of the larger
antibody moiety.
Here, we report on the construction and characterisation of such
novel fully human immunoRNase, made up of Erb-hcAb and
HP-RNase, expressed in mammalian cell cultures.
This new immunoconjugate, called anti-ErbB2 human compact
antibody-RNase (Erb-hcAb-RNase), has shown to fully retain
the binding ability, ADCC and CDC properties of Erb-hcAb and to
acquire the RNase activity of its enzymatic moiety, thus inhibiting
tumour cell proliferation in vitro and in vivo more efficiently than
the parental Erb-hcAb.
MATERIALS AND METHODS
Cell cultures and antibodies
The SKBR3 cell line from human breast cancer and the A431 cell
line from human epidermoid carcinoma were cultured in RPMI
1640 (Gibco BRL, Life Technologies, Paisley, UK). The TUBO cell line
from a BALB-neu T mouse-derived mammary lobular carcinoma
(kindly provided by Dr G Forni, University of Turin, Italy) was
grown in DMEM (Gibco BRL). The media were supplemented with
10% fetal bovine serum (20% for TUBO cells), 50Uml
 1 penicillin
and 50mgml
 1 streptomycin (all from Gibco BRL).
The antibodies used were Trastuzumab (Genentech, South San
Francisco, CA, USA); affinity-isolated IgGs from a rabbit anti-
HP-RNase antiserum (from Igtech, Salerno, Italy); horseradish
peroxidase (HRP)-conjugated goat anti-rabbit immunoglobulins
(Pierce, Rockford, IL, USA); HRP-conjugated goat anti-human
affinity-isolated IgGs (Fc specific) (Sigma, St Louis, MO, USA);
Erb-hcAb was produced by PER.C6 cells (Crucell NV, Leiden,
Netherlands) transfected with the recombinant vector (De Lorenzo
et al, 2004b), and purified as previously described (De Lorenzo
et al, 2004b).
Peripheral blood lymphocytes
Peripheral blood lymphocytes (PBL) were obtained from periph-
eral blood mononuclear cells isolated by centrifugation on
Lymphoprep gradients (Axis Shield PoC AS, Oslo, Norway) from
normal donor buffy coats obtained from the Blood Bank of the
Medical School of the University of Naples ‘Federico II’. After the
separation, PBL were washed twice and incubated in RPMI 1640
medium (Gibco BRL) for 2h at 371C to remove adherent cells. The
non-adherent cells were used as natural cytotoxic effectors without
any additional treatment.
Construction and production of the anti-ErbB2 Erb-hcAb-
RNase
The cDNA coding for the human compact antibody Erb-hcAb (De
Lorenzo et al, 2004b) was amplified from plasmid pIg1plus (R & D
Systems, Minneapolis, MN, USA) by PCR using as forward and
reverse primers oligonucleotides containing at their 50 and 30 ends
an SalI and an NotI site, respectively: 50-ACGCGTCGACCAGGTGC
AGCTGTTG-30;5 0-ATAAGAATGCGGCCGCTTTACCCGGAGACA
GG-30. The PCR fragment was then digested with SalI and NotI
(New England Biolabs, Hertfordshire, UK) for cloning into the
eukaryotic pCMV-endoplasmic reticulum (ER)-myc expression
vector (Invitrogen, Carlsbad, CA, USA) downstream to the leader
ER signal peptide sequence.
In order to obtain the chimeric construct, the gene fragment
coding for the HP-RNase was cloned downstream to the Erb-hcAb
sequence by inserting a spacer encoding an 11-amino-acid peptide
linker (AAASGGPEGGS) between the scFv-Fc and the RNase. The
cDNA coding for HP-RNase and the peptide spacer, previously
generated (De Lorenzo et al, 2004a) with NotI restriction sites at its
30 and 50 ends, was digested with NotI and cloned into the
corresponding site of pCMV-ER-myc vector downstream to the
sequence encoding the human Erb-hcAb.
The correct directional insertion of the RNase gene in the NotI
sites was assessed by digestion with suitable endonucleases (New
England Biolabs). Sequence analyses confirmed the expected DNA
sequence.
The fusion protein was produced by transfecting 293 T (human
embryonic kidney) cells with the recombinant vector. In brief, cells
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sgrown in DMEM containing 10% FCS at 70–80% confluency were
transfected with 5mg of expression vector by using the Superfect
reagent (Qiagen, Valencia, CA, USA). Stable transfectants were
selected in the presence of G418 (Sigma) at a concentration of
1mgml
 1. The expression of the antibody construct was
determined in the culture medium by quantitative ELISA. For
recombinant protein production, transfected 293T cells were
expanded to near confluence in selective DMEM medium contain-
ing 0.5mgml
–1 G418, 4mgml
–1 glucose, 10% fetal bovine serum,
50Uml
 1 penicillin, 50mgml
 1 streptomycin and were then grown
for 3–4 days in serum-free medium.
The recombinant fusion protein, henceforth termed Erb-hcAb-
RNase, secreted by transfected 293T cells, was purified from
culture medium by affinity chromatography on a protein
A-Ceramic Hyper DF column (Pall Corporation, Port Washington,
NY, USA) loaded with 300–500ml of conditioned medium, washed
with 10 volumes of 100mM Tris–HCl, pH 8.0 containing 0.5 M
NaCl and 10 volumes of 10mM Tris–HCl, pH 8.0. The protein
eluate was obtained with 50mM glycine pH 3.0, and immediately
neutralised with 1/10 volume of 1 M Tris–HCl, pH 8.0.
RNase activity and inhibition
RNase activity was tested with the acid-insoluble RNA precipitation
assay as described previously (Bartholeyns et al, 1977) on yeast RNA
(8mgml
–1). RNase zymograms, carried out on SDS–PAGE electro-
pherograms, were performed as previously described (Blank et al,
1982; De Lorenzo et al, 2004a). For inhibition assays, appropriate
amounts of Erb-hcAb-RNase and Erb-hRNase were pre-incubated
with increasing concentrations of cRI at 371C for 10min before
starting the activity test mentioned above. Ribonuclease inhibitor
was purchased from Promega (Madison, WI, USA); its concentration
was determined as previously described (Naddeo et al, 2005).
ELISA assays
ErbB2-positive SKBR3 cells and ErbB2-negative A431 control cells,
harvested in non-enzymatic dissociation solution (Sigma), were
washed and transferred to U-bottom microtitre plates (1 10
5 cells
per well). After blocking with PBS containing 6% bovine serum
albumin (BSA), cells were incubated with conditioned medium or
purified immunoagents in ELISA buffer (PBS/BSA 3%) for 90min.
The pelleted cells were washed, resuspended in 100ml of ELISA
buffer and incubated with an anti-human IgG (Fc specific) MAb
(Sigma) for detection of Erb-hcAb and Erb-hcAb-RNase. The latter
was detected also with an anti-HP-RNase IgG antibody followed by
HRP-conjugated goat anti-rabbit immunoglobulin. After 1h, the
plates were centrifuged, washed with ELISA buffer and reacted
with 3,30,5,50-tetramethylbenzidine (Sigma). Binding values were
determined from the absorbance at 450nm, and reported as the
mean of at least three determinations (s.d. p5%).
Analyses on cell cultures and lysates
Cells were seeded in 96-well, flat-bottom plates; SKBR3 cells at a
density of 1.5 10
4 well; A431 at a density of 5 10
3 well. After
incubation at 371C for 72h with the protein under test, viable cells
were counted by the Trypan blue-exclusion test. Cell viability was
determined in triplicate by using methyl tetrazolium test (Sigma)
according to the manufacturer’s recommendations. The resulting
absorbance at 570nm was measured in a microplate counter
(Multilabel Counter Victor 3, Perkin-Elmer, Waltham, MA, USA).
Cell survival was expressed as percentage of viable cells in the
presence of the protein under test, with respect to control cultures
grown in the absence of the protein. Typically, s.d. were below 5%.
SKBR3 cell extracts were prepared as previously described
(De Lorenzo et al, 2007). Protein concentration was determined by
the Bradford colorimetric assay (Sigma), and aliquots of 20mg were
run on 12% SDS–PAGE, followed by electroblotting onto PVDF
membranes (Millipore Corporation, Bedford, MA, USA).
Intracellular Erb-hcAb-RNase was detected with anti-HP-RNase
or anti-Fc IgGs, respectively, followed by goat anti-rabbit
HRP-conjugated IgGs. The signal from secondary antibodies was
visualised by enhanced chemiluminescence detection (ECL
western blotting detection kit, Amersham Biosciences, Uppsala,
Sweden). The signal intensity of reactive bands was measured with
a phosphorimager (GS-710, Bio-Rad, Hercules, CA, USA).
ADCC and CDC tests
Target and control cells were detached from culture dishes with a
cell dissociation solution (Sigma) and transferred to round-bottom
96-well plates (2 10
4 cells per well). For ADCC assays, target or
control cells were treated with the immunoagents (5mgml
 1 of
serum-free medium) and PBL at 371C for 3–4h. For CDC assays,
cells were incubated at 371C with human serum. Cultures were
performed in triplicate in a final volume of 200ml. Controls
included target cells incubated in the absence of effector cells or in
the presence of either serum or immunoagent alone. Tumour cell
lysis was determined by measuring the release of lactate
dehydrogenase (LDH) using an LDH detection kit (Roche,
Mannheim, Germany). Antibody-dependent cellular cytotoxicity
or CDC was calculated as the per cent of cytolysis measured in the
presence of immunoagent and PBL or human serum, for ADCC
and CDC, respectively, taking as 100% the maximal LDH release
determined by lysis of target cells with 1% Triton X-100. Standard
deviations were calculated on the basis of the results obtained from
three different experiments.
In vivo antitumour activity
All experiments were performed with 6-week-old female Balb/
cAnNCrlBR mice (Charles River Laboratories, Calco, Italy). The
TUBO cells (5 10
5) were suspended in 0.2ml sterile PBS and
injected subcutaneously (day 0) in the right paw. At day 7, when
tumours started to appear, the mice were divided into three
groups. At day 15, when tumours were clearly detectable,
Erb-hcAb-RNase dissolved in PBS was administered i.p. at doses
of 1.8mgkg
 1 of body weight for seven times at 72h intervals. The
second group of animals was treated with equimolar doses
(1.3mgkg
 1 of body weight) of Erb-hcAb, dissolved in PBS and
administered i.p. for seven times at 72h intervals. The third group
of control animals was treated with identical volumes of sterile PBS.
To test the effects of Trastuzumab, used as a control, the
experiment was repeated on the same model. The TUBO cells
(5 10
5) were suspended in 0.2ml sterile PBS and injected
subcutaneously (day 0) in the right paw. When tumours were clearly
detectable, Trastuzumab dissolved in PBS was administered i.p. at
doses of 2mgkg
–1for seven times at 72h intervals. The second group
of control animals was treated with identical volumes of sterile PBS.
During the period of treatment, tumour volumes (V) were
measured with caliper and calculated by the formula of rotational
ellipsoid V¼A B
2/2 (A is the axial diameter, B the rotational
diameter). All mice were maintained at the animal facility of the
Department of Cellular and Molecular Biology and Pathology,
University of Naples ‘Federico II’. Animal studies were conducted
in accordance with the Italian regulation for experimentation on
animals. All in vivo experiments were carried out with ethical
committee approval and met the standards required by the
UKCCCR guidelines (Workman et al, 1998).
Statistical analysis
Analysis of variance followed by a post hoc Dunnett’s t-test was
used to analyse the data. A P-value o0.05 was considered to be
significant.
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Production and purification of a novel fully human
anti-ErbB2 compact antibody-RNase conjugate
A new human anti-ErbB2 immunoagent was generated by fusing
HP-RNase with the fully human anti-ErbB2 compact antibody
(Erb-hcAb) (De Lorenzo et al, 2004b). The cDNAs coding for the
human compact antibody Erb-hcAb and HP-RNase were amplified
by PCR and cloned into the eukaryotic pCMV-ER-myc expression
vector. In particular, the cDNA encoding HP-RNase was cloned
downstream to the sequence encoding the carboxy terminus of the
scFv-Fc (Erb-hcAb) by adding a spacer encoding a 11-amino-acid
residue peptide linker (AAASGGPEGGS) to minimise the steric
hindrance between the two moieties of the chimeric protein
(Figure 1). The recombinant plasmid, sequenced to confirm
faithful cloning, was stably transfected in 293 T (human embryonic
kidney) cells, and the recombinant construct was expressed as a
secretion product into the culture medium. Once selected by
quantitative ELISA assays, the clone producing the highest levels of
Erb-hcAb-RNase was used for the production of the chimeric
immunoagent, which was then purified by affinity chromatography
on a protein A-Ceramic Hyper DF column. The immunoagent was
named Erb-hcAb-RNase .
Characterisation of Erb-hcAb-RNase
When Erb-hcAb-RNase was analysed by SDS–PAGE (Figure 2), it
was found to migrate under reducing conditions with the expected
molecular size of about 70kDa (Figure 2, lane B), and as a dimer of
about 140kDa under non-reducing conditions (Figure 2, lane C).
This result indicates that the fusion protein is expressed as a
disulphide-linked dimer. Western blotting analyses performed
with either an anti-human Fc or an anti-HP-RNase antibody
demonstrated immunoreactivity of the purified, dimeric protein
with a molecular size of 140kDa (Figure 2, lanes D and E).
The fusion protein was then tested for enzymatic activity by a
zymogram, developed using yeast RNA as a substrate. As
illustrated in Figure 2 lane F, a single active band was detectable,
corresponding to the size of Erb-hcAb-RNase. In a parallel assay,
the first generation anti-ErbB2 immunoRNase (Erb-hRNase),
made up of the Erbicin scFv and HP-RNase, was used as a
positive control (data not shown).
The ribonucleolytic activity of the purified Erb-hcAb-RNase was
further tested with the acid-insoluble RNA precipitation assay
(Bartholeyns et al, 1977), by which the chimeric immunoagent was
found to have a specific activity of 730±25 unitsnmol
–1. This
result was confirmed for several preparations of the recombinant
fusion protein. Because the specific activity of hErb-hRNase, that is
the monomeric anti-ErbB2 immunoRNase, previously tested, is
950±25unitsnmol
–1 (De Lorenzo et al, 2004a), we can conclude
that Erb-hcAb-RNase retains about 80% of the activity of the first
generation ImmunoRNase.
To determine the sensitivity of Erb-hcAb-RNase to RI inhibi-
tion, the enzymatic assays were repeated in the absence or in the
presence of increasing concentrations of RI. Erb-hRNase was used
as a positive control, as it was previously found to be fully
inihibited by RI (De Lorenzo et al, 2007).
As shown in Figure 3, the novel chimeric protein was found to
be susceptible of inhibition by RI, even though it was found to be
less sensitive than the monomeric immunoRNase. Indeed, the new
ImmunoRNase retains a residual 30% of the enzymatic activity
even at a cRI/IR ratio of about 5, whereas the activity of the
monomeric IR is completely inhibited at a cRI/IR ratio of about 1
(Figure 3).
This result could be considered not surprising as the larger
molecular size of the antibody fragment of Erb-hcAb-RNase with
respect to that of the scFv in Erb-hRNase could hinder the
interactions between RI and the RNase. When the ability of the
recombinant fusion protein to bind to ErbB2-positive cells was
analysed by ELISA assays (Figure 4), Erb-hcAb-RNase was found
to fully retain the specificity and the affinity of the parental
compact antibody for mammary carcinoma ErbB2-overexpressing
N
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Figure 1 Schematic representation of the chimeric ImmunoRNase,
Erb-hcAb-RNase, obtained by fusing the human compact antibody
Erb-hcAb and the HP-RNase. Erbicin¼the human anti-ErbB2 scFv;
H¼hinge; CH2-CH3¼the heavy constant domains of the human IgG1 Fc;
S¼the spacer peptide AAASGGPEGGS linking the scFv-Fc and the RNase
moieties; HP-RNase¼the RNase moiety.
140 kDa
70 kDa
Figure 2 SDS–PAGE and western blotting analyses of purified
Erb-hcAb-RNase. Erb-hcAb-RNase was run under reducing (lane B) or
non-reducing (lane C) conditions; molecular weight standards are in lane A;
western blotting analyses of the purified sample with an anti-human IgG1
(Fc specific) (lane D) or with the anti-HP-RNase antibody (lane E);
Zymogram of Erb-hcAb-RNase using yeast RNA as a substrate in lane F.
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Figure 3 Effects of the RNase inhibitor (RI) on the enzymatic activity of
the immunoRNases (IR). Inhibition by RI of the catalytic activity of the anti-
ErbB2 Erb-hcAb-RNase (circles) or Erb-hRNase (rhomboids) was
measured at increasing RI/IR ratios.
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human epidermoid carcinoma), which express very low levels of
ErbB2. The apparent binding affinity of Erb-hcAb-RNase for the
ErbB2 receptor, that is the concentration corresponding to half-
maximal saturation, was about 1nM, identical to that of the
parental Erb-hcAb.
These results demonstrate that the compact antibody and the
RNase retain their biological functions in the chimeric protein.
Biological effects of Erb-hcAb-RNase on ErbB2-positive
tumour cells
To assess the in vitro effects of Erb-hcAb-RNase on tumour cell
growth, the ErbB2-positive SKBR3 and the ErbB2-negative A431
cell lines were incubated with increasing concentrations of
Erb-hcAb-RNase, Erb-hcAb or Trastuzumab, used as a control.
As shown in Figure 5A, Erb-hcAb-RNase inhibited the growth of
SKBR3 cells in a dose-dependent manner, showing an antiproli-
ferative effect more potent than that observed for either the
parental Erb-hcAb or Herceptin. The immunoagent did not have
any effect on the proliferation of ErbB2-negative A431 cells (see
Figure 5A).
These findings suggest that the increased cyotoxicity of
Erb-hcAb-RNase with respect to that of Erb-hcAb is due to its
RNase moiety, which can exert its enzymatic activity upon
internalisation mediated by the antibody moiety.
To test the ability of the immunoRNase to be internalised by
ErbB2-positive cells, we analysed the level of Erb-hcAb-RNase in the
cytosol of treated cells. Briefly, SKBR3 cells were treated with the
immunoRNase (100nM) for 16–48h at 371C, stripped of surface-
bound protein with a low pH glycine/NaCl buffer and lysed.
Equal protein amounts of cell extracts were analysed by
immunoblotting using either anti-Fc or anti-HP-RNase IgGs,
followed by HRP-conjugated secondary antibodies. A strong
immunoreactive band with the molecular weight expected for the
immunoRNase was observed in the intracellular fraction of treated
cells (see Figure 5B), whereas no signal was detected in the extracts
of untreated control cells.
These results indicate that the immunoRNase is internalised by
ErbB2-positive cells and reaches the cytosol, where potential RNA
targets are, so that the RNase can express its cytotoxic action.
To investigate whether Erb-hcAb-RNase was capable of recruit-
ing immune effector functions in vitro, assays for cytolysis of
tumour cells as induced by PBL, or complement, were performed.
To determine the capacity of Erb-hcAb-RNase to selectively trigger
ADCC towards antigen-expressing cells, SKBR3 and A431 cells
were incubated for 3h with increasing amounts of effector PBL in
the absence or in the presence of Erb-hcAb-RNase (5mgml
 1). We
used as positive controls both Erb-hcAb and Trastuzumab. As
shown in Figure 6A, Erb-hcAb-RNase lysed SKBR3 target cells in
the presence of PBL with an efficacy slightly lower than that of the
parental Erb-hcAb. The extent of lysis reached almost 80% of
treated cells at a ratio of 100:1 (effector to target cells), whereas
Trastuzumab induced about 65% lysis at the same ratio. No effects
were detected when Erb-hcAb was replaced by the parental
anti-ErbB2 scFv, lacking the Fc domain or when Erb-hcAb-RNase
was tested in parallel assays carried out with ErbB2-negative A431
cells (data not shown), thus demonstrating the specificity of the
Erb-hcAb-RNase-dependent cell-mediated cytolytic activity (see
Figure 5).
Thus, we can conclude that the presence of the RNase in the
new construct does not affect significantly the interactions between
the Fc region of Erb-hcAb and the CD16 receptor of the natural
killer cells.
To test the ability of Erb-hcAb-RNase of inducing CDC against
ErbB2-positive tumour cells, SKBR3 target cells were incubated for
6h with Erb-hcAb-RNase (10 or 30mgml
 1) in the absence or in
the presence of human serum as a source of complement. As
illustrated in Figure 6B, Erb-hcAb-RNase was found to effectively
lyse SKBR3 cells in the presence of serum with an average specific
lysis of 40% after 6h, whereas the parental Erb-hcAb induced
about 60% lysis. Complement-dependent cytotoxicity was not
detected when the parental anti-ErbB2 scFv, lacking the Fc
domain, was used as a negative control (see Figure 6B), or when
ErbB2-negative A431 cells were incubated with Erb-hcAb-RNase
and human serum (data not shown). Similarly, as previously
reported (Drebrin et al, 1988; De Lorenzo et al, 2004b), no lysis
was detectable when SKBR3 cells were treated with Trastuzumab in
the presence of human serum (see Figure 6B).
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by enzyme-linked immunoadsorbent assay with Erb-hcAb-RNase (black
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Figure 5 In vitro effects of Erb-hcAb-RNase on tumour cells. (A) Dose–
response curves of ErbB2-positive SKBR3 (black symbols) and ErbB2-
negative A431 cells (empty symbols), treated for 72h with Erb-hcAb-
RNase (squares). The effects of Erb-hcAb (rhomboids) and Trastuzumab
(triangles), used as a positive control, are also shown. (B) Intracellular levels
of Erb-hcAb-RNase. The internalisation of Erb-hcAb-RNase by target cells
was measured (three experiments) by western blotting with an anti-RNase
(upper panel) and an anti-Fc antibody (lower panel). Lanes 1–4 (both
panels): immunoreactive proteins in the cytosolic fraction of cells untreated
(lane 1) or treated with Erb-hcAb-RNase (for: 16h, lane 2; 24h, lane 3;
48h, lane 4).
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For in vivo studies, Erb-hcAb-RNase was tested on murine TUBO
tumour cells expressing ErbB2 of rat origin (Rovero et al, 2000).
When administered to female mice, TUBO cells induce tumours
very similar to the alveolar-type human lobular mammary
carcinomas (Di Carlo et al, 1999).
In order to compare the in vivo antitumour efficacy of this novel
immunoagent with that of the parental Erb-hcAb, the effects of
equimolar doses of Erb-hcAb and Erb-hcAb-RNase were tested in
parallel on the same experimental model. In particular, to detect
the differential potency of the two immunoagents, they were
administered at lower doses than those used for peritumoural
administrations of Erb-hcAb in the previous experiment
(De Lorenzo et al, 2004b) when a dramatic reduction (96%) in
tumour volume was observed. As shown in Figure 7, the treatment
of mice bearing TUBO tumours with seven doses, at 72h intervals,
of 1.8mgkg
 1 of Erb-hcAb-RNase induced a significant reduction
(about 50%) in tumour volume and showed more potent
antitumour effects than those observed for the parental Erb-hcAb
(doses of 1.3mgkg
 1).
As a further control, we tested in a parallel experiment the
effects of equimolar doses of Trastuzumab on the same experi-
mental model. As shown in Figure 7B, Trastuzumab was found to
have a very limited inhibitory action on the growing tumours with
respect to that of Erb-hcAb-RNase. This may be interpreted by
considering that humanised Trastuzumab maintains at the
antigen-binding site structural determinants of mouse origin,
which engender a poor fit with the rat antigen, a negative feature,
which is not shared by the human antigen-binding structure of
Erb-hcAb.
During the period of treatment, the animals did not show signs
of wasting or other visible signs of toxicity.
DISCUSSION
Immunotoxins, based on toxins fused to antibody moieties
specifically reactive to a certain type of tumour cells, have been
designed for a novel approach in anticancer therapy. However, the
non-specific toxicity of ITs associated to vascular leak syndrome
and/or hepatotoxicity, as well as the immunogenicity of their
bacterial or plant toxins, have often limited the outcome of ITs as
anticancer drugs (Weiner et al, 1989; Reiter and Pastan, 1998;
Schindler et al, 2001).
To circumvent these problems, IRs, based on the IT principle,
have been proposed (Rybak and Newton, 1999; De Lorenzo et al,
2002a; De Lorenzo and D’Alessio, 2008). In the IRs, the toxin
moiety of ITs is replaced by a non-toxic and non-immunogenic
RNase, which becomes toxic only upon its internalisation
mediated by the antibody moiety in the target cells.
We previously reported on a fully human immunoRNase
obtained by fusing a human scFv and a human RNase (De
Lorenzo et al, 2004a), named Erb-hRNase, which is directed to the
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Figure 6 Antibody-dependent and CDC assays of Erb-hcAb-RNase.
(A) SKBR3 cells treated with PBL as effector cells at four different ratios in
the presence of Erb-hcAb-RNase (grey bars), Erb-hcAb (black bars),
Trastuzumab (striped bars) used as positive controls or Erbicin, the parental
anti-ErbB2 scFv (white bars), used as a negative control. Histogram
represents a summary data of multiple experiments. Bars represent
means±s.d. (*Po0.05; **Po0.01). (B) SKBR3 cells were incubated for 6h
in the presence of human serum as a source of complement with
Erb-hcAb-RNase (grey bars), Erb-hcAb (black bars), used as a positive
control, Herceptin (striped bars) or Erbicin (white bars), used as a negative
control, at concentrations of 10 and 30mgml
 1. Data are reported as the
mean of three independent experiments. Bars represent means±s.d.
(*Po0.05; **Po0.01).
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Figure 7 In vivo antitumour effects of Erb-hcAb-RNase and Trastuzu-
mab. (A) In vivo antitumour effects of Erb-hcAb-RNase. Tumour growth
was followed in mice inoculated s.c. with 5 10
5 TUBO mammary
carcinoma cells. Control animals (empty circles) were treated with sterile
PBS solution. Treated animals were injected with Erb-hcAb-RNase (black
squares), starting at day 14. Seven doses, each of 1.8mgkg
 1 of body
weight, were administered at 72h intervals i.p. In a parallel experiment, Erb-
hcAb (black rhomboids) was administered at equimolar doses
(1.3mgkg
 1) as indicated for Erb-hcAb-RNase, for comparison.
(B) In vivo antitumour effects of Trastuzumab. Tumour growth was
followed in mice inoculated s.c. with 5 10
5 TUBO mammary carcinoma
cells. Control animals (empty circles) were treated with sterile PBS solution.
Treated animals (black rhomboides) were injected with Trastuzumab,
starting at day 14. Seven doses, each of 2mgkg
 1 of body weight, were
administered at 72h intervals i.p.
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breast carcinoma (Slamon et al, 1987; Nahta et al, 2006).
Erb-hRNase was found to exert a powerful and selective
antitumour action in vitro and in vivo. However, its successful
therapeutic use could be somewhat limited by the lack of antibody
effector functions, as well as by its monovalent nature and by its
small size (o50kDa), which could be responsible for a reduced
tumour retention and a faster clearance from the blood circulation,
respectively.
In this study, we report on the production and characterisation
of a novel second generation fully human IR targeting the ErbB2
receptor called Erb-hcAb-RNase.
It results from the fusion of the fully human anti-ErbB2 compact
antibody Erb-hcAb (De Lorenzo et al, 2004b) with HP-RNase. We
have shown here that both the antibody and RNase moieties
preserve their biological actions in the immunoconjugate. This
second generation immunoRNase is endowed with the following
properties:
1. it recognises one of the most specific tumour-associated
antigens, such as ErbB2, with an affinity comparable with that
of the parental compact antibody;
2. it retains the enzymatic activity of the first generation
immunoRNase (Erb-hRNase) but, at difference with the
monovalent IR, it is only partially susceptible to RI inhibition;
3. it displays effective antibody effector functions with an efficacy
comparable with that of the parental Erb-hcAb;
4. it inhibits efficiently the proliferation of ErbB2-positive tumour
cells both in vitro and in vivo with antitumour effects more
potent than those observed for the parental compact antibody.
The latter results can be explained by the additional toxic
action of the internalised RNase;
5. the size of Erb-hcAb-RNase should be better suited for
therapeutic applications due to the potential prolonged half-
life with respect to the first generation scFv-based IR and to
better penetration properties than full size IgG-toxin immuno-
conjugates.
It has been already reported by Menzel et al (2008) on a
powerful anti-CD30 scFv-Fc-RNase, made up of a CD30 lymphoma
specific human scFv-Fc fused to HP-RNase, showing specific
binding and in vitro cytotoxicity on CD30þ lymphoma cells at nM
concentrations. However, this IR was not tested for its effector
functions (ADCC and CDC) and for its in vivo antitumour activity.
To our knowledge, Erb-hcAb-RNase is to date the first fully
human antibody-RNase to be constructed and tested with
satisfactory results in vivo demonstrating for the first time that
the presence of the RNase does not hinder the antibody effector
functions (ADCC and CDC).
On the basis of its fully human nature and selectivity of its
antitumour action on target cells, Erb-hcAb-RNase represents a
promising valuable tool in cancer therapy, thus supporting the
hypothesis that the scFv-Fc-RNase format is the most appropriate
for the production of a novel generation of IR better suited for
therapeutic applications, as it combines the advantages of the first
generation IR with those of functional relevant antibody domains.
However, the efficacy of this immunoRNase could be further
improved for a more efficient killing, as required for a successful
cancer therapy, by replacing the native human RNase with a more
cytotoxic variant resistant to the RI.
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